The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Acumen is the latest player to take aim at amyloid, but competition is fierce.
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.